IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 1.55 (2012 - 2016). 

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
A Prospective Observational Study to Compare the Effects of Methyldopa and Labetalol in Pregnancy Induced Hypertension

Author: HETA SHAH, RK GOYAL, GM VYAS, DR SHAH, BA VYAS
Abstract: Pregnancy induced hypertension (PIH) is an important cause of maternal-perinatal morbidity as well as mortality. Despite the availability of a range of antihypertensive medicines, unavoidable adverse outcomes are observed. The aim of the study was to monitor the effects of alpha methyl dopa and labetalol and its feto-maternal outcomes in pregnancy. This prospective observational study was carried out in a tertiary hospital and Maternity home in Bardoli, Gujarat. Pregnant womens’ demographic particulars, obstetric history, medication details and treatment outcomes were gathered from following up of patients. Study describes the average dose of methyldopa and labetalol required to control BP to be 1026.3± 366.63 mg and 164.3± 48.79 mg respectively in a single drug therapy plan and 950± 34.30 mg and 200 mg in a combination therapy group respectively. In both, alpha methyldopa and labetalol group, the average gestational age for development of PIH was 31 weeks. There was no statistical difference in the age of patients among different treatment arms. In all treatment groups, majority of the pregnant women were primi gravida. In combination therapy group high rate of preterm delivery (20%) as well as C-section delivery (86.7%) was observed. Simultaneously minimum baby weight (0.5 kg) was also found to be in combination therapy group. Methyldopa was the most commonly prescribed antihypertensive drug. Labetalol is a more potent drug to achieve adequate control of blood pressure. Despite utilization of standard antihypertensive drugs high rates of caesarean section and IUGR conclude that conventional antihypertensive treatment is a controller rather than preventer.
Keyword: PIH, Bardoli, methyl dopa, labetalol, feto-maternal outcomes
Download: Request For Article
 












USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events
hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477